Hemogenyx Pharmaceuticals PLC Director/PDMR Shareholding (6565X)

TIDMHEMO

RNS Number : 6565X

Hemogenyx Pharmaceuticals PLC

01 May 2019

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that it has been advised that on 30 April 2019 Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), purchased 840,336 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") at a price of 2.38p per share. Following this transaction, Mr Wright now has a total beneficial interest in 840,336 Ordinary Shares, representing approximately 0.23 per cent of the Company's issued share capital.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 
 1.   Details of PDMR/person closely associated with them 
       ("PCA") 
 a)   Name                            Andrew Wright 
     ------------------------------  ------------------------------------------------ 
 b)   Position/status                 Financial Controller and Company Secretary/PDMR 
                                       (non-board) 
     ------------------------------  ------------------------------------------------ 
 c)   Initial notification/           Initial notification 
       amendment 
     ------------------------------  ------------------------------------------------ 
 2.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place where 
       transactions have been conducted 
     -------------------------------------------------------------------------------- 
 a)   Description of                  Ordinary shares of 1p of Hemogenyx 
       the financial                   Pharmaceuticals plc 
       instrument                      Identification code GB00BYX3WZ24 
     ------------------------------  ------------------------------------------------ 
 b)   Nature of the                   Acquisition of ordinary shares 
       transaction 
     ------------------------------  ------------------------------------------------ 
 c)   Price(s) and volume(s)           Price(s)         Volume(s) 
                                        GBP GBP0.0238    840,336 
                                                        ---------- 
     ------------------------------  ------------------------------------------------ 
 d)        Aggregated information      Price(s)            Volume(s) 
             *    Aggregated volume     GBP GBP20,000.00    840,336 
                                                           ---------- 
 
             *    Price 
     ------------------------------  ------------------------------------------------ 
 e)   Date of the transaction         2019-04-30 
     ------------------------------  ------------------------------------------------ 
 f)   Place of the transaction        London Stock Exchange 
                                       XLON 
     ------------------------------  ------------------------------------------------ 
 

Enquiries:

 
 Hemogenyx Pharmaceuticals plc              www.hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive      [e-mail] 
  Officer & Co-Founder 
 Sir Marc Feldmann, Executive Chairman 
 
 SP Angel Corporate Finance LLP             Tel: [phone] 
                                             0470 
 Matthew Johnson, Vadim Alexandre, Soltan 
  Tagiev 
 
 Peterhouse Corporate Finance Limited       Tel: [phone] 
                                             0930 
 Lucy Williams, Duncan Vasey 
 
 US Media enquiries 
 Lowell Goodman                             Tel: [phone] 
                                             or [e-mail] 
 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHDGGDSDXXBGCG

(END) Dow Jones Newswires

May 01, 2019 02:01 ET (06:01 GMT)